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Background: Puerto Rico is among the areas with the highest estimated rates of people
living with HIV in the United States. Despite the epidemiologic data available, there is
limited real-world information that can help understand the comorbidities of people with
HIV. In this study, we describe common comorbidities among adults with HIV attending
treatment clinics in Puerto Rico.
Methods: An exploratory, retrospective, cross-sectional study was conducted at five HIV
clinics in Puerto Rico. A random sample of medical records was reviewed. Descriptive
statistics were used to summarize patient demographics, morbidity, and clinical character-
istics. Multivariate analyses were conducted to explore comorbidities by age and sex.
Results: A total of 250 (179 men; 71 women) medical records were reviewed. Participants’
mean age was 47.9 years and on average they had been living with HIV for 9 years. Most
(97.6%) had at least one comorbidity. The most common comorbidities were dyslipidemia
and hypertension. Men were more likely to have been diagnosed with alcohol misuse while
women were more likely to have been diagnosed with obesity, human papillomavirus (HPV),
hypothyroidism, and osteoporosis. Participants younger than 50 years of age were more
likely to have history of alcohol misuse while older individuals (50 years and old) were more
likely to have been diagnosed with dyslipidemia, hypertension, and diabetes. Adjusting by
sex and age, women were more likely to have been diagnosed with obesity and depression
and those older than 50 years were more likely to have had a diagnosis of dyslipidemia,
hypertension, HPV, and diabetes.
Conclusions: This is one of the few studies assessing comorbidities among adults with HIV in
Puerto Rico, among Latino/Hispanics within the United States, and Latin America. Consistent
with other studies, cardiovascular diseases are common among adults with HIV in Puerto Rico.
Findings support the need for awareness and real-world evidence about comorbidities among
people with HIV when implementing screenings and prescribing drugs.
Keywords: HIV, comorbidities, Puerto Rico
Background
HIV continues to be a significant public health issue, and despite advances in
prevention and care services, further work is needed to improve the well-being of
people living with HIV. Globally, in 2017, more than 940,000 people died of HIV-
related illnesses, 36.9 million were HIV-positive, and 1.8 million people became
newly infected.1 By 2015, and according to the Centers for Disease Control and
Prevention (CDC),2 Puerto Rico was among the areas with the highest estimated
rates of adults and adolescents with diagnosed HIV infection (17.1 per 100,000) in
the United States (US) and dependent areas. By May 2019, there were 49,675
known HIV infections in Puerto Rico.3 The incidence of HIV in the island is one of
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the highest rates in the United States4 and almost double
the overall US Hispanic/Latino population.5,6
In Puerto Rico, the number of HIV/AIDS cases and the
number of deaths have reduced substantially throughout
the years, lowering the case fatality rate from 82% in 1985
to 2% in 2016.7 Further, in a recent report by Marzán-
Rodríguez and colleagues,8 it was documented that of all
the deaths among people with HIV in Puerto Rico from
2006 to 2011, less than a quarter (23.5%) were related to
HIV/AIDS.
People diagnosed with HIV infection may have an
increased risk of developing comorbidities compared to
the general population due to HIV disease itself and the
use of long-term antiretroviral therapy (ART).9–20 As HIV
survival has increased and persons living with HIV enjoy
life expectancies similar to those without HIV infection,
they are likely to share the same comorbidities. For exam-
ple, heart disease is among the comorbidities typically
seen among people with HIV.21–24 Coincidentally, heart
disease was the second leading cause of death in Puerto
Rico in 2013.25 Furthermore, the Behavioral Risk Factor
Surveillance System (BRFSS) has evidenced relatively
high prevalence of high cholesterol (36.7), hypertension
(44.7), and diabetes (17.2%) among adult residents in
Puerto Rico.26 In addition, nearly two-thirds are either
overweight or obese, a risk factor for Coronary Heart
Disease (CHD), and 43.4% has been estimated to have
metabolic syndrome.27 In a recent assessment of CHD risk
of patients attending physician offices in Puerto Rico, a
substantial number of patients whose records were
reviewed had risk factors for developing CHD and nearly
one-third of the sample had a 10% or more 10-year risk of
developing CHD.28
In spite of the availability of mortality and prevalence
data, there is a lack of real-world published information
that would help to understand the comorbidities of people
with HIV in Puerto Rico. Such information is of great
importance to create awareness among health care provi-
ders and the health care system overall about the needs of
taking into consideration the comorbidities of people with
HIV when planning screening tests and prescribing any
medication that they may need.
Methods
To understand comorbidities in a sample of adult HIV-
positive individuals in Puerto Rico, an exploratory, retro-
spective, cross-sectional study was conducted between
January and April 2015. Data were collected from five
clinics that provide services to people with HIV in differ-
ent geographical areas in Puerto Rico. Clinics were purpo-
sively chosen to provide diversity to the sample and based
on disposition to collaborate in the study. A State Health
Department HIV Clinic, a Municipal Health Department
HIV Clinic, and three private/non-governmental HIV
Clinics provided the sample for the study. Both publicly
funded and private-owned clinics were included.
Sample
A random sample of medical records was reviewed. At
each clinic, a simple random selection was used to select
medical records to be reviewed. The eligibility criteria to
select and review a medical record included having an
HIV diagnosis, at least 21 years of age, and being engaged
in care in the selected clinic during the last 6 months.
Patients with an AIDS diagnosis and pregnant women
were excluded from the study due to additional medical
conditions associated with their health status. Similarly,
individuals enrolled in clinical trials at the time of data
collection or during the last six months prior to their
medical chart revision were excluded from the sample.
Measurements
Following an extensive narrative literature review and clin-
ician’s recommendations, an in-depth data collection instru-
ment was created, allowing for the recollection of HIV
clinical information, as well as patient history of numerous
comorbidities, lipids, glucose and creatinine data, and
comorbidities treatment history. Patient’s demographic
information were also collected. All data collected were
based on the information available in the medical record
of each patient at the selected clinics. Comorbidities were
collected from the medical record using different sources of
information, including problem list, referral notes, and pro-
gress notes.
Analysis
Data collection was completed using a paper and pen
survey-like instrument, and then data were transferred to
an electronic dataset using the Questionnaire Development
System (QDS, Nova Research Company). Descriptive sta-
tistics (ie, mean, standard deviation) was used to summar-
ize patient demographics, morbidity, and clinical
characteristics. Multivariate analyses (ie, MANOVA,
Multiple Regression Analysis) were conducted to explore
differences by age and sex. For age-related analysis, 50
years of age were selected to dichotomize the sample and
Rodríguez-Díaz et al Dovepress
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this is consistent with CDC definition of older people with
HIV.29 SPSS v.20 was used to conduct all statistical pro-
cedures. Authorization was sought and received from each
clinic before submitting to the Institutional Review Board
(IRB). All study procedures were approved by the Human
Research Subjects Protection Office of the University of
Puerto Rico-Medical Sciences Campus.
Results
Demographic and clinical characteristics
As included in Table 1, a total of 250 medical records were
reviewed. Of these, 179 were of men (71.6%) and 71
(28.4%) of women. The mean age of the subjects was
47.9 years and, on average, they had been living with
HIV for 9.3 years. Data availability for this research did
not differ by sex. Certainly, as a result of good practices in
HIV care, patients who have been living longer with a
diagnosis of HIV infection had more information in their
medical records.
On average, the age for HIV diagnosis among partici-
pants was 38 years; they spent 9.4 years from HIV diag-
nosis to treatment initiation and have been on treatment for
3.4 years. The mean CD4 count was 723.8 cells/mm3, and
for viral load, the count was 3,431.1 copies/mL.
Considering the role that body max index (BMI) may
have with certain comorbidities, bivariate analyses were
conducted to assess the BMI by sex and age. As included
in Table 2, more than a third of the study sample was
overweight. Among men, 62.6% had an abnormal BMI,
while 35.2% of the women were obese. These differences
were statistically significant by sex.
When BMI was assessed by age groups (younger than
50 years of age and 50 years of age and older), more than a
third (37.0%) of those younger than 50 years of age had a
normal BMI, and 40.4% of those 50 years of age or older
were overweight. These differences by age groups were
not found to be statistically significant. See Table 2 for
details.
Comorbidities
The vast majority (97.6%) of the participants had been diag-
nosed with at least one HIV comorbidity during the 6-month
period that preceded data collection. Among the most com-
mon comorbidities for both men and women were dyslipide-
mia (total: 60.8%; men: 60.8%; women: 69.0%), alcohol
abuse (total: 48.8%; men: 58.1%; women: 25.4%), and
hypertension (total; 39.6%; men: 36.9%; women: 46.5%).
Table 3 includes all the comorbidities found in the study
sample. In general, the mean amount of comorbidities
reported in the sample was 3.7 (SD=1.9). Men reported
significantly less comorbidities (Mean=3.5, SD=1.9) than
women (Mean=4.1, SD=1.9; p=0.035).
As included in Table 3, when all comorbidities where
assessed by sex, men were more likely to have been
diagnosed with alcohol misuse (p<0.001) while women
were more likely to have been diagnosed with obesity
(p=0.001), HPV infection (p=0.002), hypothyroidism
(p=0.006), and osteoporosis (p=0.003).
Table 1 General characteristics of a sample of adults with HIV in Puerto Rico
Characteristics Total (N=250) Men (N=179) Women (N=71)
μ SD μ SD Μ SD
Age 47.9 12.6 46.3 13.3 51.8 9.8
Weight (lbs) 169.9 38.7 170.7 34.0 168.1 48.7
Height (in) 67.4 6.0 69.0 6.2 63.3 2.7
Body mass index 26.6 6.0 25.5 5.0 29.3 7.4
Age when diagnosed with HIV 38.0 11.6 37.0 12.0 40.6 9.8
Age of HIV treatment initiationa 39.6 12.5 37.7 13.1 44.7 9.3
Diagnosis to HIV treatment (months)a 9.4 17.1 9.0 15.5 10.6 20.8
Years living with HIV 9.3 8.1 8.8 8.0 10.6 8.0
Years in HIV treatmenta 3.4 3.6 3.0 3.6 4.2 3.4
Days since last CD4 test 80.2 75.7 79.8 65.2 81.1 97.6
CD4 count (cells/mm3) 723.8 363.2 698.7 326.8 786.6 437.6
CD4 percentage 34.8 30.4 34.6 35.1 34.9 30.4
Days since last viral load test 81.4 84.6 82.7 76.7 78.1 102.2
Viral load countb (copies/mL) 3431.1 14,342.9 4174.3 16,670.5 1628.7 5348.1
Notes: aN=103 (Men=74, Women=29). bn=137 (Men=97, Women=40).
Dovepress Rodríguez-Díaz et al
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The data collection instrument also included a general
clinical assessment of indicators of common comorbidities
and chronic conditions. As included in Table 4, data on
blood pressure, lipid panel, and blood chemistry tests were
obtained from medical records. Overall, the research sam-
ple showed slightly higher levels for triglycerides, glucose,
hemoglobin A1c, and systolic blood pressure when com-
pared to normal values. When analyzed by sex, women
had LDL levels slightly higher than normal. There were no
statistically significant findings when these clinical indica-
tors were assessed by age.
As included in Table 5, the most common comorbidity
treatments were multivitamins (71.5%), lipid-lowering ther-
apy (57.6%), and antihypertensive agents (37.6%). These
were also the most common treatments when stratified by
sex. The mean amount of medications in the study sample
Table 2 Bivariate analysis of body mass index categorized by sex and age in a sample of adults with HIV in Puerto Rico
Comorbidity Total (N=250) Men (N=179) Women (N=71) p-Value <50 yrs (N=135) 50+ yrs (N=114) p-Value
N % n % n % n % n %
Body mass index 0.001 0.360
<20 26 10.4 21 11.7 5 7.0 12 8.9 14 12.3
20–<25 84 33.6 67 37.4 17 23.9 50 37.0 33 28.9
25–<30 90 36.0 66 36.9 24 33.8 44 32.6 46 40.4
30+ 50 20.0 25 14.0 25 35.2 29 21.5 21 18.4
Note: Values in bold represent statistical significance (<0.05).
Table 3 Comorbidities in a sample of adults with HIV in Puerto Rico
Comorbidity Total Men (N=179) Women (N=71) p-Value
n % n % N %
Prevalence of comorbidities 244 97.6 174 97.2 70 98.6 0.519
Dyslipidemia 152 60.8 103 57.5 49 69.0 0.094
Alcohol miuse 122 48.8 104 58.1 18 25.4 <0.001
Hypertension 99 39.6 66 36.9 33 46.5 0.161
Cigarette Smoking 89 35.6 67 37.4 22 31.0 0.337
Overweight 67 26.8 46 25.7 21 29.6 0.532
Diabetes mellitus 49 19.6 32 17.9 17 23.9 0.276
Depression 48 19.2 29 16.2 19 26.8 0.056
Obesity 48 19.2 25 14.0 23 32.4 0.001
Substance misuse 42 16.8 33 18.4 9 12.7 0.272
Human papilloma virus (HPV) 42 16.8 22 12.3 20 28.2 0.002
Chronic hepatitis C 33 13.2 24 13.4 9 12.7 0.878
Vitamin D deficiency 24 9.6 15 8.4 9 12.7 0.298
Hypothyroidism 20 8.0 9 5.0 11 15.5 0.006
Chronic hepatitis B 12 4.8 7 3.9 5 7.0 0.330
Chronic kidney disease 10 4.0 5 2.8 5 7.0 0.153
Lipodystrophy 9 3.6 8 4.5 1 1.4 0.452
Osteoporosis 9 3.6 2 1.1 7 9.9 0.003
Benign prostatic hyperplasia 7 2.8 7 3.9 – – –
Peripheral vascular disease 6 2.4 5 2.8 1 1.4 0.999
Revascularization Procedure 6 2.4 4 2.2 2 2.8 0.999
Acute coronary syndrome (ACS) 5 2.0 5 2.8 0 – 0.326
Pre-diabetes 5 2.0 3 1.7 2 2.8 0.624
Angina pectoris 4 1.6 3 1.7 1 1.4 0.999
Previous stroke/TIA 2 0.8 0 – 2 2.8 0.080
Congestive heart failure 1 0.4 1 0.6 0 – 0.999
Note: Values in bold represent statistical significance (<0.05).
Rodríguez-Díaz et al Dovepress
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was of 2.1 (SD =16). Men were using less medications
(Mean =2.5, SD =1.5) than women (Mean =3.5, SD =1.6,
p<0.001).
Further, when compared to men, women were more
likely to be using proton pump inhibitors (p<0.001) and
anti-acids (p=0.030, See Table 5).
To explore age-related factors associated with comor-
bidities, the sample was dichotomized in two age groups,
younger than 50 years of age and 50 years of age and
older. As included in Table 6, the group younger than 50
years were more likely to have an alcohol abuse diagnosis
(p=0.006) while the older individuals (50 years of age or
older) were more likely to have been diagnosed with
dyslipidemia (p<0.001), hypertension (p<0.001), and dia-
betes mellitus (p<0.001).
Considering the role of age in developing comorbidities,
a multivariate analysis adjusting by sex and age was con-
ducted. Findings suggest that women were more likely than
men to have been diagnosed with obesity (aOR=3.197; 95%
CI: 1.625–6.290) and depression (aOR=1.986; 95% CI:
1.008–3.914). Also, as included in Table 7, they were
slightly more likely than men to have been diagnosed with
alcohol abuse (aOR=0.266; 95% CI: 0.143–0.496), HPV
infection (aOR=0.282; 95% CI: 0.136–0.584), and
hypothyroidism (aOR=0.300; 95% CI: 0.116–0.779).
Comorbidities associated with been older than 50 years of
Table 4 Blood pressure, lipid panel, and blood chemistry tests data from a sample of adults with HIV in Puerto Rico
Clinical indicator Total (N=250) Men (N=179) Women (N=71)
μ SD Μ SD μ SD
Non-HDLa 36.7 31.0 37.5 32.0 35.0 29.3
Total cholesterol 177.9 41.7 175.0 42.5 185.3 38.8
HDL 46.1 16.1 44.6 14.8 50.0 18.4
LDL 99.8 34.1 98.3 34.2 103.7 33.7
Triglycerides 185.7 179.1 191.3 194.9 171.7 131.7
Glucose (FPG) 101.6 33.1 101.4 31.3 101.9 131.7
Hemoglobin A1c (HgbA1c)b 6.1 1.5 6.2 1.7 6.1 0.9
Blood pressure
Systolic 128.3 17.5 127.6 16.4 130.1 19.8
Diastolic 79.4 10.7 79.0 11.0 80.4 10.0
Creatinine (Cr) 1.0 0.6 1.0 0.6 0.8 0.7
Notes: aN=167 (Male=113; Female=54). bn=93 (Male=65; Female=28).
Table 5 Treatment history of a sample of adults with HIV in Puerto Rico
Treatment Total (N=250) Men (N=179) Women (N=71) p-Value
n % n % n %
Anti-acids 8 3.2 3 1.7 5 7.0 0.030
Antihyperglycemic agents 41 16.4 30 16.8 11 15.5 0.807
Antihypertensive agents 94 37.6 63 35.2 31 43.7 0.213
Asthma medications 28 11.2 17 9.5 11 15.5 0.175
Cholecalciferol 80 32.0 51 28.5 29 40.8 0.059
Dehydroepiandrosterone 3 1.2 3 1.7 0 – –
H2 blockers 42 16.8 25 14.0 17 23.9 0.057
Levothyroxine 15 6.0 7 3.9 8 11.3 –
Lipid-lowering therapy 144 57.6 97 54.2 47 66.2 0.083
Multivitamins 178 71.5 123 68.7 55 78.6 0.121
Opioid pain medication 2 0.8 2 1.1 0 – –
Proton pump inhibitors 46 18.4 21 11.7 25 35.2 <0.001
Note: Values in bold represent statistical significance (<0.05).
Dovepress Rodríguez-Díaz et al
HIV/AIDS - Research and Palliative Care 2019:11 submit your manuscript | www.dovepress.com
DovePress
159
 
H
IV
/A
ID
S 
- R
es
ea
rc
h 
an
d 
Pa
llia
tiv
e 
Ca
re
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
18
7.
16
3.
59
.2
6 
on
 2
5-
Ju
l-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
age were dyslipidemia (aOR=3.075; 95% CI: 1.769–5.346),
hypertension (aOR=2.852; 95% CI: 1.670–4.871), HPV
infection (aOR=2.547; 95% CI: 1.205–5.385), and diabetes
mellitus (aOR=3.331; 95% CI: 1.684–6.589).
Discussion
While not a representative sample of people with HIV in
Puerto Rico, data from participants in this study are
similar to the general epidemiological data available of
people with HIV and to other studies conducted among
people with HIV in Puerto Rico. The ratio of women and
men with HIV in the sample (1:3) is consistent with
surveillance data from the Puerto Rico Department of
Health.7 Other general similarities with previously pub-
lished research are participant’s average age30,31 and
hemoglobin levels.32
Consistent with other studies among people with HIV, the
sample studied in this research evidenced comorbidities asso-
ciated with cardiovascular diseases.33 For example, dyslipide-
mia is a comorbidity reported among other similar populations.
In our study, the prevalence of dyslipidemia was higher than
the rates reported among HIV-positive adults (43.7% Latinos)
in the Bronx, NY (60.8% vs 48%).33
The five most common comorbidities in this sample of
people with HIV in Puerto Rico slightly varied from the find-
ings from a study published by Miranda and colleagues34 also
encompassing a sample of HIV-positive individuals in the
island. In their longitudinal study among people with HIV,
they found that the most common comorbidities were cardio-
vascular diseases, renal and hepatic disorders, osteopenia,
endocrine and metabolic abnormalities, and non-AIDS defin-
ing neoplasm. The difference between these studies might be
the inclusion/exclusion of patients with anAIDS diagnosis and
Table 6 Bivariate analysis of the prevalence of comorbidities by age in a sample of adults with HIV in Puerto Rico
Comorbidity <50 yrs (N=135) 50+ yrs (N=114) p-Value
n % N %
Prevalence of comorbidities 131 97.0 113 99.1 0.242
Alcohol abuse 77 57.0 45 39.5 0.006
Dyslipidemia 66 48.9 86 75.4 <0.001
Cigarette smoking 55 40.7 34 29.8 0.073
Hypertension 38 28.1 61 53.5 <0.001
Overweight 34 25.2 33 28.9 0.505
HPV 28 20.7 14 12.3 0.076
Substance misuse 27 20.0 15 13.2 0.151
Obesity 27 20.0 21 18.4 0.753
Depression 27 20.0 21 18.4 0.753
Diabetes mellitus 15 11.1 34 29.8 <0.001
Chronic hepatitis C 13 9.6 20 17.5 0.067
Vitamin D deficiency 10 7.4 14 12.3 0.194
Hypothyroidism 9 6.7 11 9.6 0.388
Chronic hepatitis B 7 5.2 5 4.4 0.769
Angina pectoris 3 2.2 1 0.9 0.627
Chronic kidney disease 3 2.2 7 6.1 0.193
Revascularization procedure 2 1.5 4 3.5 0.417
Pre-diabetes 2 1.5 3 2.6 0.663
Lipodystrophy 2 1.5 7 6.1 0.084
Osteoporosis 2 1.5 7 6.1 0.084
Benign prostatic hyperplasiaa 2 1.9 5 7.1 0.114
Previous stroke/TIA 1 0.7 1 0.9 0.999
Peripheral vascular disease 1 0.7 5 4.4 0.096
Acute coronary syndrome (ACS) 0 – 5 4.4 0.019
Congestive heart failure 0 – 1 0.9 0.458
Tuberculosis 0 – 0 – –
Fat accumulation 0 – 0 – –
Notes: aOnly men were included when analyzing benign prostatic hyperplasia (n=178). Values in bold represent statistical significance (<0.05).
Rodríguez-Díaz et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
HIV/AIDS - Research and Palliative Care 2019:11160
 
H
IV
/A
ID
S 
- R
es
ea
rc
h 
an
d 
Pa
llia
tiv
e 
Ca
re
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
18
7.
16
3.
59
.2
6 
on
 2
5-
Ju
l-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
the longitudinal nature of the study conducted byMiranda and
colleagues.34 It is our understanding that our findings illustrate
a better picture of the comorbidities of people with HIV in
Puerto Rico who are engaged in care.
Another study conducted among people with HIV in
Puerto Rico found morbidity and mortality associated with
kidney disease.30 However, in this sample, history of
comorbidity with kidney disease was low (<20%) and no
alarming levels of clinical indicators of kidney disease (ie,
creatinine) were reported.
Consistent with other research findings from studies
with people with HIV, when compared to men, women
show higher rates of overweight and obesity.31,35 A study
conducted by Ramirez-Marrero and colleagues36 reported
the risk for metabolic syndrome among people with HIV
in Puerto Rico. Consistent with their findings, our analysis
supports the needs for monitoring cardiovascular indica-
tors among people with HIV. Furthermore, our findings –
consistent with those of Maldonado-Martínez and
colleagues35 from a sample of people with HIV in Puerto
Rico – support the needs for comprehensive approaches to
reduce the risk for metabolic syndrome and HIV disease
progression, including monitoring BMI as well as chronic
and behavioral precursors.
The most common comorbidities found in older groups
after controlling by sex are consistent with findings
reported in the scientific literature. A significant finding
in this regard is the fact that dyslipidemia among those
participants 50 years and older was 3.075 (95% CI: 1.769–
5.346) more common than among those younger than 50
years. This is more than double the likelihood of this
correlation (OR=1.42) found in a sample of individuals
45 years or older from The Bronx, New York.33 Future
studies among patients older than 50 years are recom-
mended to assess HIV-induced accelerated aging.
While the purpose of this study was not to assess HIV
comorbidities with mental illnesses in details, significant
rates of depression and substance abuse were found. Due
to the fact that injecting drug use is one of the main risk
factors for HIV infection in Puerto Rico, it is not surprising
Table 7 Multivariate analysis of the prevalence of comorbidities by age and sex in a sample of adults with HIV in Puerto Ricoa
Comorbidity Sex Age
Men Women <50 yrs 50+ yrs
Ref. aOR (95% CI) Ref. aOR (95% CI)
Prevalence of comorbidities 1 1.258 (0.133–11.891) 1 3.313 (0.354–31.040)
Alcohol abuse 1 0.266 (0.143–0.496) 1 0.595 (0.349–1.013)
Dyslipidemia 1 1.288 (0.697–2.379) 1 3.075 (1.769–5.346)
Cigarette smoking 1 0.821 (0.450–1.498) 1 0.641 (0.374–1.098)
Hypertension 1 1.181 (0.658–2.119) 1 2.852 (1.670–4.871)
Overweight 1 1.162 (0.623–2.168) 1 1.177 (0.663–2.088)
HPV 1 0.282 (0.136–0.584) 1 2.547 (1.205–5.385)
Drug abuse 1 0.703 (0.312–1.581) 1 0.644 (0.320–1.298)
Obesity 1 3.197 (1.625–6.290) 1 0.700 (0.357–1.372)
Depression 1 1.986 (1.008–3.914) 1 0.785 (0.407–1.514)
Diabetes mellitus 1 1.118 (0.558–2.240) 1 3.331 (1.684–6.589)
Chronic hepatitis C 1 0.790 (0.340–1.836) 1 2.085 (0.971–4.474)
Vitamin D deficiency 1 0.706 (0.288–1.733) 1 0.611 (0.255–1.462)
Hypothyroidism 1 0.300 (0.116–0.779) 1 0.859 (0.331–2.230)
Chronic hepatitis B 1 1.990 (0.591–6.707) 1 0.727 (0.217–2.439)
Angina pectoris 1 1.020 (0.100–10.432) 1 0.388 (0.038–3.941)
Chronic kidney disease 1 2.175 (0.592–7.992) 1 2.461 (0.603–10.047)
Revascularization procedure 1 1.046 (0.181–6.054) 1 2.398 (0.418–13.768)
Pre-diabetes 1 1.513 (0.237–9.656) 1 1.655 (0.261–10.516)
Lipodystrophy 1 0.217 (0.026–1.808) 1 5.348 (1.073–26.656)
Osteoporosis 1 7.831 (1.548–39.622) 1 2.929 (0.573–14.986)
Peripheral vascular disease 1 0.345 (0.039–3.075) 1 7.202 (0.816–63.535)
Notes: aAcute coronary syndrome, congestive heart failure, tuberculosis, previous stroke/TIA, and fat accumulation were excluded from this analysis due to lack of
reported cases in certain subgroups. Benign prostatic hyperplasia was also excluded from the analysis. Values in bold represent statistical significance (<0.05).
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to identify these comorbidities in a sample of people with
HIV in the archipelago. In our study, 48.8% of the sample
reported alcohol misuse. In other studies of people with
HIV, alcohol use had varied from 5% (measuring alcohol
abuse) to 51.5%.32,33,37 Nonetheless, different from other
investigations conducted in Puerto Rico,34,35 in our study
we found that, after adjusting by age and sex, women had
higher likelihood of been diagnosed with alcohol misuse.
This finding, as other findings reported in this manuscript,
requires further analysis considering the role that sex differ-
ences may play in access and healthcare use.38
On the other hand, cigarette smoking was reported
among more than a third of the participants (35.6%) and
substance misuse was documented in 16.8% of the study
sample. Other studies have reported rates from 13% to
59.4% of cigarette smoking33,36,39 and from 3% (reporting
only drug abuse) to 43.7% of substance misuse.32,33 The
findings of our study are consistent with those from other
studies reporting higher rates of substance misuse (non-
alcohol or cigarettes) among men.34,35
Findings from this study should be considered in con-
text with population-based data available regarding the
most common comorbidities in Puerto Rico. For example,
it has been documented that among adults in Puerto Rico
(irrespective of their HIV status) about 36.7% (36.6%
among men; 36.7% among women) have reported a high
level of cholesterol in blood;13.1% (20.5% among men;
6.8% among women) have reported binge drinking; 11.3%
have reported current smoker status (16.9% among men;
6.4% among women); and 68.3% of the population is
overweight or obese (70.2% among men; 66.6% among
women).26 These population trends have an impact in the
assessment of comorbidities among people with HIV in
Puerto Rico and the interpretation and comparisons with
findings from studies conducted with populations else-
where. Moreover, these population health indicators high-
light the significance of the findings of this study and the
need to integrate public health prevention efforts.
Research findings should be considered within the lim-
itations of this study. This research project was limited to
the revision of 250 medical charts from 5 clinics. These
clinics were selected following a purposive sampling
approach and the 250 medical charts reviewed were cho-
sen based on a simple random selection. Further, due to
the retrospective and cross-sectional nature of this study,
data are limited to the information available from the chart
reviews. No data were collected related to the use of ART
limiting the analysis of the relationship of HIV-related
medication and comorbidities. Similarly, the charts
selected for revision are of those participants who met
inclusion criteria and were active in medical care. As a
result of all the aforementioned limitations, findings are
not generalized to people with HIV in Puerto Rico or
elsewhere.
Conclusion
Based on a comprehensive narrative analysis of the scien-
tific literature, and to the best of our knowledge, this is the
first observational study that assessed comorbidities
among people with HIV in Puerto Rico and one of the
few among Latino/Hispanic populations. Despite the lim-
itations of the study and consistent with other studies,
cardiovascular diseases – specifically dyslipidemia and
hypertension – were found to be common among people
with HIV in Puerto Rico. Certain characteristics such as
age, sex, and use of medication may play a role in the
comorbidities among people with HIV in Puerto Rico.
Findings support the need for creating awareness of the
comorbidities of people living with HIV, particularly when
implementing prevention strategies and prescribing drug
therapy. Further, this information should be available to
physicians and other health care providers to improve
differentiated and comprehensive approaches to address
the needs of people with HIV.
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Abbreviation list
AIDS, acquired immune deficiency syndrome; ART, anti-ret-
roviral therapy; BMI, body mass index; BRFF, Behavioral
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Risk Factors Surveillance System; CD4, cluster of differentia-
tion 4; CHD, coronary health disease; FPG, fasting plasma
glucose; HDL, high-density lipoprotein; HgbAic, glycosylated
hemoglobin; HIV, human immunodeficiency virus; HPV,
human papilloma virus; H2 blockers, histamine H2-receptor
antagonists; LDL, low-density lipoprotein; QDS,
Questionnaire Development System; SD, standard deviation;
TIA, transient ischemic attack; US, United States.
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